Key result
Preprocedural NYHA class IV predicts ~75% higher 2-year mortality vs class II/III after M-TEER.
Why the study?
Whether preprocedural NYHA class IV continues to predict outcomes after successful mitral regurgitation reduction with M-TEER in primary mitral regurgitation remained unclear.
Does preprocedural NYHA class IV predict worse outcomes compared to NYHA class II/III in patients with primary mitral regurgitation undergoing M-TEER?
Cohort (n=2,528)
Yes
Does preprocedural NYHA class IV predict worse outcomes compared to NYHA class II/III in patients with primary mitral regurgitation undergoing M-TEER?
Hazard Ratio: 1.75 (95% CI 1.32–2.31)
Absolute Event Rate: 31.8% vs 21.1%
p-value: p=< 0.001
In patients with primary mitral regurgitation undergoing M-TEER, preprocedural NYHA class IV is an independent predictor of 2-year all-cause mortality despite achieving comparable procedural success to less symptomatic patients.
NYHA class IV flags high-risk PMR patients for M-TEER; leaves open whether preprocedural optimization improves survival.
Background In patients with primary mitral regurgitation (MR) (PMR), advanced symptoms classified as New York Heart Association (NYHA) class IV are typically driven by valve deterioration. Transcatheter edge-to-edge repair (mitral valve transcatheter edge-to-edge repair [M-TEER]) reliably achieves effective reduction of mitral regurgitation in high-risk patients. However, whether or not preprocedural NYHA class IV continues to predict outcomes after successful MR reduction remains unclear.Methods The Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry includes PMR patients undergoing M-TEER at 27 international sites between 2009 and 2023. Clinical outcomes were compared between patients in NYHA class IV and those in NYHA class II/III.Results A total of 2528 patients were included (median age 82 years [interquartile range (IQR) 76-85], 45.9% female), and 19.7% presented in NYHA class IV. Baseline left ventricular ejection fraction and right ventricular function did not differ significantly between groups. Procedural success (residual MR ≤ 1+: 66.7% vs. 64.6%, p = 0.55) and 2-year rehospitalization rates (17.9% vs. 20.4%, log-rank p = 0.78) were comparable. In contrast, 2-year all-cause mortality was higher in NYHA class IV patients (31.8% vs. 21.1%, log-rank p < 0.0001). Multivariable Cox regression confirmed preprocedural NYHA class IV as an independent predictor of mortality (hazard ratio [HR] 1.75; 95% CI 1.32-2.31; p < 0.001).Conclusions In PMR, preprocedural NYHA class IV remains an independent predictor of all-cause mortality after effective MR reduction with M-TEER, despite comparable postprocedural results.
No takes yet. Share an insight, caveat, or question.
Koell et al. (2026) conducted a cohort in Primary mitral regurgitation (n=2,528). Preprocedural NYHA class IV vs. NYHA class II/III was evaluated on 2-year all-cause mortality (HR 1.75, 95% CI 1.32-2.31, p=< 0.001). Preprocedural NYHA class IV independently predicted higher 2-year all-cause mortality compared to NYHA class II/III after M-TEER for primary mitral regurgitation (HR 1.75; 95% CI 1.32-2.31; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: